Form 4: Integrated BioPharma Director Acquires 50,000 Stock Options

Sentiment:

SEC Form 4 Filing


Robert Canarick, a director of Integrated BioPharma, Inc., acquired 50,000 stock options on August 7, 2024, exercisable at $0.18.

Summary

  • On August 7, 2024, Robert Canarick, a director at Integrated BioPharma, Inc. (INBP), acquired 50,000 stock options.
  • The exercise price for these options is $0.18 per share.
  • The options vest in four equal installments of 12,500 each on September 30, 2024, December 31, 2024, March 31, 2025, and June 30, 2025.
  • The expiration date for these options is August 7, 2034.
  • Following the transaction, Canarick directly owns 50,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, indicating a standard transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

  • The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

DateDescription
08/07/2024Date of transaction: Robert Canarick acquired 50,000 stock options.
09/30/2024First vesting date: 12,500 stock options vest.
12/31/2024Second vesting date: 12,500 stock options vest.
03/31/2025Third vesting date: 12,500 stock options vest.
06/30/2025Fourth vesting date: 12,500 stock options vest.
08/07/2034Expiration date of the stock options.
08/08/2024Date of signature.

Keywords

stock options, Form 4, director, INBP, Integrated BioPharma, beneficial ownership, Robert Canarick

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.